July 14 (Reuters) - British drugmaker GSK said
on Monday it had submitted an application to the U.S. Food and
Drug Administration to extend the use of its respiratory
syncytial virus (RSV) vaccine, Arexvy, to adults under the age
of 50 at a higher risk of the disease.